Special Note Regarding Forward-Looking Statements
This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of preclinical studies and clinical trials and other development activities; the unpredictability of the duration and results of regulatory review; market acceptance for approved products and innovative therapeutic treatments; competition; the potential not to receive partnership milestone, profit sharing or royalty payments; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning us and such risks and uncertainties is available on our website and in our press releases and in our public filings with the U.S. Securities and Exchange Commission. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

This presentation concerns products that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). No representation is made as to their safety or effectiveness for the purposes for which they are being investigated.
Transforming Antibody Therapeutics in Cancer

**Probody™ Platform**
- Antibody prodrug platform to enable first-in-class and best-in-class treatments
- Designed to enhance tumor targeting and widen therapeutic window
- Deep scientific know-how afforded by a decade of scientific research
- >160 CytomX-owned patents and patent applications

**Pipeline Strategies**
- Immunotherapies directed against clinically-validated targets
  - CX-072 (PD-L1), PD-1, CTLA-4
- Novel first-in-class therapeutics directed against difficult-to-drug targets
  - CX-2009 (CD166-PDC), CD71-PDC
- Emerging applications for T-cell bispecifics and CARs

**Partners**
- abbvie
- Bristol-Myers Squibb
- Pfizer
- IMMUNOGEN
- MD Anderson Cancer Center

**Financial**
- $181 million cash balance as of March 2016; provides funding through 2018
- $20-25 million cash burn in 2016

**Milestones**
- **2016**: CX-072 (PD-L1) IND Filing
- **2016**: Potential partner milestones
- **2017**: CX-2009 (CD166) IND Filing (1H)
- **2017/2018**: Initial clinical results

PROBODY and IHZ are trademarks of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are the property of their respective owners.
PROBODY PLATFORM
Emerging Potent Modalities Limited by Toxicity

<table>
<thead>
<tr>
<th>TOXICITY</th>
<th>Checkpoint Inhibitors(^1)</th>
<th>Antibody Drug Conjugates(^2)</th>
<th>T-Cell Bispecifics(^3)</th>
<th>CARs/TCRs(^4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhagic and/or coagulation in 5/6 patients in Phase I at the lowest dose tested</td>
<td>Ipi/nivo</td>
<td>Anti-EphA2</td>
<td>EGFR/CD3</td>
<td>NY-ESO-1 MART1</td>
</tr>
<tr>
<td>Organ inflammation in cynomolgus monkeys</td>
<td>Development discontinued</td>
<td>Early termination of study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55% Gr 3-4 Toxicity (treatment-related)</td>
<td>36% Drug Stopped</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**After more than 35 years of clinical development:**
- None of the approved mAbs that directly bind tumor cells are tumor specific
- All can mediate on-target and off-tumor toxicities\(^5\)

---

Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment

ANTI-CANCER ANTIBODY

PROTEASES

LINKER

MASKING PEPTIDE

TUMOR

TUMOR

TUMOR
Activated Proteases are Prevalent in Tumors But Not in Healthy Tissue

- Upregulated protease activity is a hallmark of all cancers
- Protease activity is tightly controlled in healthy tissues

Probody Therapeutic Activation by Proteases in Xenograft, PDX and Human Tumors *in situ*

Red Staining = Probody Activation by Protease

<table>
<thead>
<tr>
<th>Xenograft Tumors</th>
<th>PDX Tumors</th>
<th>Human Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC</td>
<td>NSCLC</td>
<td>NSCLC</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Colon cancer</td>
<td>Breast cancer</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Pancreatic cancer</td>
<td>Pancreatic cancer</td>
</tr>
</tbody>
</table>

IHZ™ assay
Blue staining = DAPI
Probody Therapeutics Localize to Tumor Tissue \textit{in vivo}

Non-binding Control Antibody  
Parent PD-L1 Antibody  
CX-072 PD-L1 Probody Tx
Preclinical Proof of Concept Achieved for Multiple Probody Modalities & Targets

Immune Modulators/Checkpoint Inhibitors
- PD-L1 (CX-072)
- PD-1
- CTLA-4

Antibody Drug Conjugates
- CD166 (CX-2009)
- CD71
- ITGA3

T-Cell Bispecifics
- EGFR-CD3

CARs

In Progress in Collaboration with MDACC
IMMUNO-ONCOLOGY PROGRAM
CX-072 (PD-L1)
CX-072 Has the Potential to Become the PD-L1 Combination Agent of Choice

CX-072 PD-L1 PROBODY THERAPEUTIC

- Validated target
- Well-established efficacy & safety for class

Kinase Inhibitors
ADCs
Other Cancer Immuno-therapies
Traditional Chemotherapy
Localizing Drug Activity to Tumor May Avoid Checkpoint Inhibitor Toxicities

- In combination, enhanced efficacy is associated with synergy of toxicities
- Localizing treatment to the tumor may achieve efficacy without toxicity
- Probody Therapeutics achieve localized effects with conventional dosing

---

**MELANOMA**

<table>
<thead>
<tr>
<th></th>
<th>Opdivo alone</th>
<th>Yervoy Alone</th>
<th>Yervoy + Opdivo¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR</td>
<td>44%</td>
<td>19%</td>
<td><strong>58%</strong></td>
</tr>
<tr>
<td>Grade 3-4 AEs*</td>
<td>16%</td>
<td>27%</td>
<td><strong>55%</strong></td>
</tr>
<tr>
<td>Stopped Drug</td>
<td>8%</td>
<td>15%</td>
<td><strong>36%</strong></td>
</tr>
</tbody>
</table>

**MELANOMA**

<table>
<thead>
<tr>
<th></th>
<th>Vemurafenib alone²</th>
<th>Atezolizumab + Vemurafenib³</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR (CR)</td>
<td>48% (1%)</td>
<td><strong>67% (33%)</strong></td>
</tr>
<tr>
<td>Grade 3-4 AEs*</td>
<td>38%</td>
<td>67%</td>
</tr>
<tr>
<td>Stopped Drug</td>
<td>NR**</td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

*Treatment-related **Not reported

CX-072 Preclinical Proof of Concept

**TUMOR GROWTH**

- Mean Tumor Volume (mm$^3$)
- Study Day
- Control
- Antibody
- Probody Tx

**SAFETY**

- Induction of Autoimmunity
- %Non- Diabetic
- Days post-dose
- Control & Probody Tx
- Antibody

**Similar Efficacy**

- Non-binding Control Antibody
- Parent PD-L1 Antibody
- CX-072 PD-L1 Probody Tx

**Localizes to Tumor**

**Autoimmunity Reduced**

**Prevents Binding in Periphery**
## Rapidly Advancing CX-072 to the Clinic

### CX-072 (PD-L1)

<table>
<thead>
<tr>
<th>Year</th>
<th>1H</th>
<th>2H</th>
<th>1H</th>
<th>2H</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### IND Enabling Studies
- File IND

#### Launch Phase I/II Study
- Dose escalation
- Monotherapy & combination(s)
- Multiple PD-1/PD-L1 sensitive cancers
  - E.g. Melanoma, NSCLC, bladder

**2H17 – 2018:**
- Report biomarker, safety and efficacy data
PROBODY DRUG CONJUGATE PROGRAMS
CX-2009 (CD166) CD71
CX-2009 Has Broad Potential Utility Across Tumor Types

CX-2009
CD166 PROBODY DRUG CONJUGATE

- Novel drug conjugate target
- Expressed in cancerous and normal tissues
- Prevalence and expression greater than usual antibody drug conjugate targets
- Clinically validated linker/payload
- Fast-to-market opportunities
CD166 PDC CX-2009 is Efficacious in Preclinical Tumor Models and Well-Tolerated in Primates

- Utilizes clinically validated spdb-DM4 payload (ImmunoGen)
- Well-tolerated at 5 mg/kg ≈ DM4 clinical dose

**CX-2009 Efficacy**

**NSCLC Tumor Growth**

- Isotype control: 5 mpk
- CD166 PDC: 5 mpk

**CX-2009 Safety**

**Liver Function Tests**

- Single 5 mg/kg dose on day 1

5 mg/kg PDC given days 0 and 7

Study Day

- Study Day
- Predose
- Day 8
- Day 22

Mean Tumor Volume (mm$^3$)

Percent Predose Value (mean ± range)
CX-2009 (CD166): Clinical Strategy

CX-2009 (CD166)

IND Enabling Studies

File IND  Launch Phase I/II Study

- Monotherapy dose escalation
- Expand to multiple cancers

2H17 – 2018:

- Report biomarker, safety and efficacy data
CD71 is a Highly Desirable Antibody Drug Conjugate Target

- Ubiquitously expressed on dividing, normal and malignant cells
- Mediates iron uptake required for cell division
- A professional internalizing protein: often used as a positive control in ADC experiments
- Expression in normal dividing cells prohibits development of a traditional ADC
CD71 Preclinical Proof of Concept

**TUMOR GROWTH**

*Cell Line-Derived Xenograft NCI-H292 (Lung)*

- IgG control ADC
- CD71-ADC
- CD71-PDC

**TOLERABILITY IN NON-HUMAN PRIMATES**

*Neutrophils*

- Count x 10^3/μL

**Similar Efficacy**

**Toxicity Reduced**

**Extended Exposure**
PARTNERSHIPS
Recently Announced Collaboration with AbbVie for Probody Drug Conjugates

**CD71**
- CytomX leads early development
- AbbVie leads later development and commercialization
- $470M aggregated in potential development, regulatory & commercial milestones
- CytomX retains profit share and co-promote in US
- Commercial milestones and royalties to CytomX ex-US

**AbbVie Targets**
- Up to 2 targets selected by AbbVie
- AbbVie responsible for development and commercialization
- Additional milestone and royalty payments per target to CytomX on any resulting products

$30 million upfront to CytomX
Major Oncology Alliances Broaden Our Pipeline

**Bristol-Myers Squibb**
- 3 target collaboration expandable to 4
- Initial target CTLA-4/Yervoy
- $60M received to date; $15M upon expansion
- Tiered royalties reaching low teens
- $1.2B in potential milestones
- PD-L1, PD-1 and other validated IO targets carved out
- Invested $10M in CTMX IPO

**Pfizer**
- Multi-target PDC alliance
- Up to $25M in upfront payments
- Preclinical funding and milestones
- Up to $610M in regulatory and sales milestones
- Tiered royalties on sales
- Invested $5M in CTMX IPO

**IMMUNOGEN**
- Access to IMGN linker/payloads for CytomX
- IMGN licenses Probody technology
- Full ownership retained for CytomX programs
- Modest reciprocal clinical milestones and royalties

**MD Anderson Cancer Center**
- Creating proCAR-NK therapies
- CAR-NK cells have the potential to be allogeneic therapies
- MD Anderson ongoing clinical studies with NK cell therapy and pre-clinical studies with CAR-NK cell therapies
SUMMARY
A Decade of Research and Strong Intellectual Property Drive our Competitive Advantage

- >160 CytomX-owned patents and patent applications
- Initial intellectual property licensed from UCSB
  - Tools, UCSB’s rights in original Probody Platform
- Deep institutional know-how

- >20 Probody therapeutics successfully designed
- Efficacy in genetic, xenograft & PDX models
- Safety window expanded up to 300-fold
- Deep protease biology expertise

- Proprietary substrate libraries
- in vivo imaging confirming local activation
- Probody-specific biomarkers
- Novel manufacturing methods
Unlocking the Potential of Antibody Therapeutics in Cancer

Strong cash position to advance our broad pipeline

Continued strategic and operational momentum since IPO

File CX-072 IND in 2H16
File CX-2009 IND in 2017

Clinical data in 2017/2018

Broad Probody Therapeutic Pipeline Poised for Proof of Concept and Value Creation